These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. [The pathogenesis of biliary stone formation and its prevention in biliary tract diseases]. Vakhrushev IaM; Khokhlacheva NA Ter Arkh; 1999; 71(2):44-8. PubMed ID: 10222553 [TBL] [Abstract][Full Text] [Related]
28. [Clinical studies on the choleretic agent Febuprol (author's transl)]. Scholing WE; Weinert W MMW Munch Med Wochenschr; 1978 Feb; 120(5):143-6. PubMed ID: 342924 [TBL] [Abstract][Full Text] [Related]
29. [Imecromone: a new choleretic with antispastic action on Oddi's sphincter. Clinical pharmacology and clinico-statistical study]. Cremoncini C; Tominz L Minerva Med; 1968 Oct; 59(82):4359-68. PubMed ID: 5683717 [No Abstract] [Full Text] [Related]
30. [Clinical trials of an association of a choleretic (1-morpholinoacetyl-3-phenyl-4-oxo-1,2,3,4-tetrahydroquinazoline hydrochloride), (Rec 14-0127) and phenolphthalein and belladonna extract]. Pozzi M Farmaco Prat; 1969 Oct; 24(10):655-62. PubMed ID: 4902987 [No Abstract] [Full Text] [Related]
31. [Therapeutic action of arginine-thiazolidine-carboxylate (ATCA) as evaluated by liver function tests]. Alvisĭ V; D'Ambrosi A; Lo Ponte A; Tampieri ML; Tralli M Arch Sci Med (Torino); 1980; 137(4):731-8. PubMed ID: 7018458 [TBL] [Abstract][Full Text] [Related]
32. [Further results of a multi-centre clinical trial with the oral antidiabetic drug glisoxepide (author's transl)]. Blumenbach L; Kiesselbach N; Lehnert J Arzneimittelforschung; 1976; 26(5):931-43. PubMed ID: 786303 [TBL] [Abstract][Full Text] [Related]
33. [Enzyme substitution therapy in digestive system diseases with special consideration of patients treated with tuberculostatic agents]. Piacenza F Med Welt; 1967 May; 21():1321-5. PubMed ID: 5612545 [No Abstract] [Full Text] [Related]
34. [Polyunsaturated phosphatidylcholine combined with vitamin B complex in the treatment of patients with disorders of the hepatobiliary function caused by unbalanced nutrition]. Cairella M; Callisto F; Godi R; Marchini G Clin Ter; 1989 Nov; 131(4):237-46. PubMed ID: 2532093 [TBL] [Abstract][Full Text] [Related]
35. [Use of a new synthetic cholerectic agent in the therapy of some gastro-duodeno-biliary and pancreatic diseases]. Azzena D Clin Ter; 1972 Apr; 61(1):47-58. PubMed ID: 5039601 [No Abstract] [Full Text] [Related]
36. [Clinical study of a synthetic choleretic: alpha-(1-hydroxy-4-phonyl-cyclohexyl)-butyric acid (MG 4833)]. Montemartini C; Fontana S; Calderoni AG Clin Ter; 1967 Jul; 42(2):121-39. PubMed ID: 5598371 [No Abstract] [Full Text] [Related]
37. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328 [TBL] [Abstract][Full Text] [Related]
38. Therapy of primary biliary cirrhosis with p-tolylmethylcarbinol nicotinic acid ester in combination with alpha-naphthylacetic acid. Kaserbacher R; Propst A; Vogel W Wien Klin Wochenschr; 1996 Nov; 108(22):722-6. PubMed ID: 8986034 [TBL] [Abstract][Full Text] [Related]
39. Double-blind study of a total liver extract in patients with hepatic dysfunction. Preziosi P; Nisticò G; Marano V Int J Clin Pharmacol Biopharm; 1975 Apr; 11(3):210-5. PubMed ID: 1097345 [TBL] [Abstract][Full Text] [Related]
40. [Clinical and radiological study of a new synthetic cholereretic agent]. Strata A; Arsenio L; Marcato M; Maccarini PA Clin Ter; 1971 Oct; 59(2):117-35. PubMed ID: 5141388 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]